{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:09:08Z","timestamp":1779253748566,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While diagnostic and therapeutic innovations have significantly improved the prognosis of hematological malignancies (HMs), comprehensive data on their survival outcomes in China remain scarce. This study aimed to investigate the up-to-date long-term survival of common HMs in a Chinese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this population-based study, we analyzed data from nine cancer registries in Taizhou, eastern China, covering patients aged \u226515 years diagnosed with HMs between 2009 and 2023. Period analysis was used to estimate overall and stratified 5-, 10-, and 15-year relative survival (RS) by sex, age at diagnosis, region, and subtype, revealing trends in RS over time since diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included a total of 10, 022 HM cases, with a median age at diagnosis of 62 years. During 2019\u20132023, the overall 5-year RS for all HMs was 57.0%. Among the three major HM types, lymphoma exhibited the highest 5-year RS (64.4%), followed by multiple myeloma (51.1%), while leukemia had the lowest (49.3%). The 10-year and 15-year RS for all HM patients decreased to 46.0% and 37.5%, respectively. Except for leukemia, females had higher 5-, 10-, and 15-year RS than males. For each type of HM, RS was significantly higher in patients aged&amp;lt;60 years than in those aged \u226560 years, and urban areas showed higher RS than rural areas. In terms of subtypes, chronic lymphocytic leukemia and chronic myeloid leukemia had the best long-term survival. The 15-year survival curves for HMs generally declined with longer time since diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study is the first to provide timely and accurate long-term survival series data for patients with HMs in Taizhou, eastern China, using period analysis. The results offer crucial evidence for optimizing public health strategies and developing targeted cancer control measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1826643","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:40:34Z","timestamp":1779252034000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaohui","family":"Mo","sequence":"first","affiliation":[{"name":"School of Public Health and Nursing, Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]},{"name":"Department of Cancer Prevention, Zhejiang Cancer Hospital","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Bing","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention, Zhejiang Cancer Hospital","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","place":["Hangzhou, Zhejiang, China"]},{"name":"Primary Health Care Department, Wuwei Maternal and Child Health Hospital","place":["Wuwei, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Hua","sequence":"additional","affiliation":[{"name":"School of Public Health and Nursing, Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]},{"name":"Department of Cancer Prevention, Zhejiang Cancer Hospital","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention, Zhejiang Cancer Hospital","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijiao","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention, Zhejiang Cancer Hospital","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xukai","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention, Zhejiang Cancer Hospital","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[{"name":"School of Public Health and Nursing, Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention, Zhejiang Cancer Hospital","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and classification of hematologic Malignancies on the basis of genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40164-025-00684-x","article-title":"Global burden and trends of hematologic Malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021","volume":"14","author":"Pan","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and etiology of leukemia and lymphoma","volume":"10","author":"Bispo","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1612702","article-title":"The global burden of leukemia and its attributable factors in 204 countries and territories: Findings from the Global Burden of Disease 2019 Study and projections to 2030","volume":"2022","author":"Du","year":"2022","journal-title":"J Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1186\/s12889-025-22376-1","article-title":"Trends and projections of Non-Hodgkin lymphoma burden (1990-2040): a global burden of disease 2021 analysis","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Public Health"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01852-w","article-title":"Survival in hematological Malignancies in the Nordic countries through a half century with correlation to treatment","volume":"37","author":"Hemminki","year":"2023","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19961101)78:9<2004::aid-cncr23>3.3.co;2-6","article-title":"An alternative approach to monitoring cancer patient survival","volume":"78","author":"Brenner","year":"1996","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24614","article-title":"Model\u2010based projections for deriving up\u2010to\u2010date cancer survival estimates: An international evaluation","volume":"125","author":"Gondos","year":"2009","journal-title":"Intl J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ijc.32866","article-title":"Assessment of long-term survival of cancer patients using cancer registry data from eastern China: Period analysis is superior to traditional methods","volume":"147","author":"Jiang","year":"2020","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62225-4","article-title":"Cancer survival: global surveillance will stimulate health policy and improve equity","volume":"383","author":"Coleman","year":"2014","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101474","article-title":"What is relative survival and what is its role in haematology","volume":"36","author":"Pohar Perme","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.03.011","article-title":"Choosing the relative survival method for cancer survival estimation","volume":"47","author":"Hakulinen","year":"2011","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.826","article-title":"Up-to-date long-term survival curves of patients with cancer by period analysis","volume":"20","author":"Brenner","year":"2002","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Cancer survival statistics in China 2019-2021: a multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jncc.2023.12.003","article-title":"Cancer survival analysis on population-based cancer registry data in Zhejiang Province, China (2018-2019)","volume":"4","author":"Li","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174388","article-title":"Epidemiological trends of haematological Malignancies in Belgium 2004-2018: Older patients show the greatest improvement in survival","volume":"15","author":"Henau","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.264","article-title":"Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2022","volume":"57","author":"Park","year":"2025","journal-title":"Cancer Res Treat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7150\/jca.52186","article-title":"Secular trends in the incidence and survival of all leukemia types in the United States from 1975 to 2017","volume":"12","author":"Yang","year":"2021","journal-title":"J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.11.005","article-title":"Long-term survival expectations of cancer patients in Europe in 2000-2002","volume":"45","author":"Brenner","year":"2009","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-4992.2023.05.029","article-title":"Survival rate and long-term change trend of NHL in Qidong from 1972 to 2016","volume":"31","author":"Xu","year":"2023","journal-title":"Modern Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study","volume":"25","author":"Sant","year":"2024","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.219","article-title":"Clinical characteristics and treatment outcomes of pediatric patients with Non-Hodgkin lymphoma in East Asia","volume":"52","author":"Suh","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012120","article-title":"Epidemiologic characteristics of Malignant lymphoma in Hubei, China: A single-center 5-year retrospective study","volume":"97","author":"Meng","year":"2018","journal-title":"Med (Balt)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115231","article-title":"Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study","volume":"220","author":"Vener","year":"2025","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41408-020-0323-4","article-title":"Changes in long term survival after diagnosis with common hematologic Malignancies in the early 21st century","volume":"10","author":"Pulte","year":"2020","journal-title":"Blood Cancer J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf181","article-title":"Comparative analysis of patients\u2019 characteristics, treatment, and survival outcomes in CLL from China and the United States","volume":"30","author":"Yan","year":"2025","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00236-4","article-title":"Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study","volume":"12","author":"Yin","year":"2025","journal-title":"Lancet Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2643-3249.BCD-20-0083","article-title":"The landscape of blood cancer research today-and where the field is headed","volume":"1","author":"Haloupek","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102441","article-title":"Cancer survival in adults in Spain: A population-based study of the Spanish Network of Cancer Registries (REDECAN)","volume":"14","author":"Guevara","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08330.x","article-title":"Late relapse in patients with diffuse large B-cell lymphoma","volume":"151","author":"Vose","year":"2010","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2018.07.003","article-title":"Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care","volume":"33","author":"Damlaj","year":"2019","journal-title":"Blood Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.6068","article-title":"Risk of subsequent solid tumors after non-Hodgkin\u2019s lymphoma: effect of diagnostic age and time since diagnosis","volume":"26","author":"Hemminki","year":"2008","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1186\/s12889-025-23469-7","article-title":"Burden of hematologic Malignancies in China from 1990 to 2021: analysis from the Global Burden of Disease Study 2021","volume":"25","author":"Shao","year":"2025","journal-title":"BMC Public Health"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.11.008","article-title":"The advantage of women in cancer survival: an analysis of EUROCARE-4 data","volume":"45","author":"Micheli","year":"2009","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the United States","volume":"9","author":"Pulte","year":"2014","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2010.04.013","article-title":"Cancer survival as a function of age at diagnosis: a study of the Surveillance, Epidemiology and End Results database","volume":"34","author":"Bassily","year":"2010","journal-title":"Cancer Epidemiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2018.01.015","article-title":"Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013","volume":"53","author":"Andres","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29227","article-title":"Cancer survival in China, 2003-2005: a population-based study","volume":"136","author":"Zeng","year":"2015","journal-title":"Int J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010690","article-title":"Disparities in survival of hematologic Malignancies in the context of social determinants of health: a systematic review","volume":"7","author":"Miranda-Galvis","year":"2023","journal-title":"Blood Adv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1826643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:40:41Z","timestamp":1779252041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1826643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1826643"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1826643","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1826643"}}